Acquired red cell aplasia

Specialty: Hematology

Recommendations:

IVIG is an option for patients with immunologic pure red cell aplasia (PRCA) who have failed other therapies (e.g. prednisone or cyclosporin). IVIG should be considered first-line therapy for viral PRCA associated with parvovirus B19 in immunocompromised patients.

Dose:

Up to 2 g/kg divided over 2 to 5 consecutive days; for short term use. Repeated on relapse.